Phase I/II Study of Avelumab in Pediatric Cancer Subjects
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, international study to evaluate the dose, safety and
tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in
pediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid
tumors (including central nervous system tumors) and lymphoma for which no standard therapy
is available or for which the subject is not eligible for the existing therapy.